Top 7 Companies in the Global Respiratory Pathogen Testing Kits Market

The global respiratory pathogen testing kits market was valued at USD 4.10 Billion in 2023, driven by the rising incidence of respiratory infections and advancements in technology across the globe. The market is anticipated to grow at a CAGR of 5.70% during the forecast period of 2024-2032, with the values likely to reach USD 6.75 Billion by 2032.

Diagnostic tools known as respiratory pathogen testing kits are used to identify infections brought on by bacteria, fungi, or viruses. Testing respiratory samples can assist in determining the cause of respiratory system illnesses such as pneumonia, COVID-19, and influenza. The market is expanding due to the growing prevalence of respiratory diseases and improvements in diagnostic technologies.

The respiratory pathogen testing kits market has witnessed significant growth in recent years, driven by the increasing prevalence of respiratory infections and the global rise in pandemics, most notably the COVID-19 crisis. The demand for rapid and accurate diagnostics has surged, especially for viral infections, which has resulted in the development of more advanced testing solutions. The market is also benefiting from ongoing technological advancements, including the integration of molecular diagnostics and PCR-based testing, which offer higher accuracy compared to traditional methods.

The growing awareness about infectious diseases and the need for early detection are major drivers of the market. Furthermore, healthcare systems are increasingly focusing on improving infection control and surveillance, further boosting demand for respiratory pathogen testing kits. The rise in home testing solutions and point-of-care diagnostics is a growing trend, with more consumers preferring to conduct tests at home for convenience and safety. As global travel and urbanisation continue to increase, the market is poised to expand further, addressing the rising global health concerns associated with respiratory illnesses.

Major Companies Shaping the Respiratory Pathogen Testing Kits Market in 2024

1.    Thermo Fisher Scientific

Thermo Fisher Scientific is a global leader in serving science, headquartered in Waltham, Massachusetts, USA. The company offers a wide range of laboratory products and services, including diagnostic testing kits. In July 2022, it launched the Applied Biosystems TaqPath Respiratory Viral Select Panel, a CE-IVD-marked molecular assay designed to detect five common respiratory viruses. This advanced testing solution is poised to drive the growth of the respiratory pathogen testing kits market by enabling faster and more accurate diagnoses, especially during peak respiratory virus seasons.

2.    Abbott Laboratories

Abbott Laboratories, based in Abbott Park, Illinois, is a major healthcare and medical diagnostics company. In March 2020, it received Emergency Use Authorization (EUA) from the FDA for its RealTime SARS-CoV-2 molecular test, which can quickly detect the COVID-19 virus. This rapid test, deployed across U.S. hospitals and labs, marked a critical milestone in responding to the pandemic. Abbott's innovation in testing technologies has significantly impacted the respiratory pathogen testing market, with continued demand for fast and reliable diagnostic tools expected to drive future growth.

3.    Danaher Corporation

Danaher Corporation is a global science and technology company based in Washington, D.C. It designs and manufactures diagnostic tools across various fields, including respiratory pathogen detection. In recent years, Danaher has focused on advancing molecular diagnostics and increasing its presence in the respiratory pathogen testing market. Through strategic acquisitions and new product development, Danaher is positioned to influence market growth, providing comprehensive solutions for the detection of respiratory infections.

4.    Becton, Dickinson and Company

Becton, Dickinson and Company (BD), headquartered in Franklin Lakes, New Jersey, is a leading global medical technology company. In February 2023, BD announced it received FDA Emergency Use Authorization for a new molecular diagnostic test on the BD MAX system, which detects SARS-CoV-2, Influenza A + B, and Respiratory Syncytial Virus (RSV). The test uses a single swab and delivers results in two hours, significantly improving testing capacity during peak seasons. This innovation is expected to drive demand in the respiratory pathogen testing kits market, improving diagnostic efficiency.

5.    F. Hoffmann La Roche Ltd.

Roche, a global leader in pharmaceuticals and diagnostics, is headquartered in Basel, Switzerland. In September 2024, Roche launched its Cobas respiratory virus test, which simultaneously detects up to 12 respiratory pathogens, including COVID-19, influenza, and RSV. This new test, compatible with the Cobas 5800, 6800, and 8800 analyzers, is expected to revolutionise the respiratory pathogen testing kits market. Roche's innovation responds to the growing demand for multi-pathogen detection, which will enhance diagnostic capabilities, especially during respiratory virus seasons.

6.    bioMerieux Inc.

bioMérieux, headquartered in Marcy-l'Étoile, France, is a world leader in in vitro diagnostics. In March 2020, its subsidiary BioFire Defense received FDA Emergency Use Authorization for the BIOFIRE® COVID-19 test, which detects SARS-CoV-2 in about 45 minutes. This highly efficient, easy-to-use test runs on the fully automated FILMARRAY® system and has been instrumental in addressing the global demand for rapid COVID-19 diagnostics. BioMérieux's continued innovation in molecular diagnostics is expected to drive growth in the respiratory pathogen testing kits market, improving workflow efficiency and diagnostic speed.

7.    Altona Diagnostics

Altona Diagnostics, headquartered in Hamburg, Germany, specialises in the development of molecular diagnostic tests. In June 2022, it launched the RealStar® Zoonotic Orthopoxvirus PCR Kit, designed to detect monkeypox and other Orthopoxviruses. The launch was in response to the global monkeypox outbreak. Altona’s innovation in viral pathogen testing is a significant development in the diagnostic market, expanding the range of respiratory and viral testing kits available. This technology will continue to influence the respiratory pathogen testing kits market, particularly in the context of emerging infectious diseases.